Table 3.
Primary study endpoint of severe (grade ≥ 3) infections
| BsAb, N = 55 | CAR-T, N = 92 | ADC, N = 109 | |
|---|---|---|---|
|
| |||
| Infection grade | 22 (40) | 24 (26) | 9 (8) |
| - grade ≥ 3 infections | 2 (4) | 0 | 1 (1%) |
| - grade 4 infections | 4 (7) | 0 | 0 |
| - grade 5 infections | |||
|
| |||
| Recurrent severe infections | 11 (20) | 6 (7) | 2 (2%) |
|
| |||
| n (%) | |||
BsAb, bispecific antibodies; CAR-T, chimeric antigen receptor T-cell therapy; ADC, antibody drug conjugate.